Clinical trials: Long QT Syndrome (LQTS)
Long QT Syndrome Type 3, Long QT Syndrome 2
Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3
This is a cross-sectional observational study designed to assess the disease burden and quality of life in individuals with LQTS 2 and 3.
- Trial name
- NCT07075445
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Thryv Therapeutics, Inc.
Long QT Syndrome
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
Part 1: This is a Phase 1b, randomized, double-blind, crossover, dose escalation, placebo-controlled study to evaluate the effect of oral LQT-1213 on dofetilide-induced QTc prolongation in healthy adult subjects.
- Trial name
- NCT05906732
- Testing
- LQT-1213, Dofetilide 250 μg Cap
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Thryv Therapeutics, Inc.
LQT2 Syndrome
Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome
The primary objective of the study is to evaluate the effect of oral eleclazine (formerly GS-6615) on corrected QT (QTc) interval in participants with long QT2 syndrome.
- Trial name
- NCT02365506
- Testing
- Eleclazine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Gilead Sciences
Long QT Syndrome
Phase 1 Study of LQT-1213 in Healthy Adults
This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD).
- Trial name
- NCT05759962
- Testing
- LQT-1213
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Thryv Therapeutics, Inc.
Long QT Syndrome
Study of the Effect of GS-6615 in Subjects With LQT-3
This mechanism of action study is to evaluate the effect of oral GS-6615 on the QTc interval in participants with Long QT-3 syndrome.
- Trial name
- NCT01849003
- Testing
- GS-6615
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Gilead Sciences
Long QT Syndrome (LQTS) 2
Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)
The goal of this clinical trial is to learn whether the study drug THRV-1268 can safely and effectively shorten the QT interval in people diagnosed with Long QT Syndrome Type 2 (LQTS 2) and Long QT Syndrome Type 3 (LQTS 3).
- Trial name
- Wave II (NCT07277582)
- Testing
- baseline lead-in, THRV-1268
- Where
- 9 sites in United States
- Volunteers
- 84 people
- Sponsor
- Thryv Therapeutics, Inc.